Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SwedenBack to Sweden

Clinical trials in Danderyd

66 clinical trials in Danderyd, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Danderyd at a glance
66
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

66 trials in Danderyd

Open in trial search

Chronic kidney disease

Recruiting

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Renal disorder

Recruiting

BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Focal segmental glomerulosclerosis

Recruiting

A study to evaluate the effects of BI 764198 in adults and adolescents with focal segmental glomerulosclerosis (FSGS)

Investigational
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Chronic kidney disease+1

Recruiting

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Acute respiratory failure

Recruiting

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Acute myocardial infarction

Recruiting

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Chronic obstructive pulmonary disease

Recruiting

Study on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Recruiting

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:SwedenSweden
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Danderyd

What the registry says about research in the country

01 Cardiovascular and Renal Studies

Innovative research focusing on chronic kidney disease treatments and cardiovascular conditions, including trials examining new therapeutic combinations for heart failure and blood pressure management.

  • Hypertension management in CKD patients
  • Heart failure with preserved ejection fraction
  • Left ventricular thrombosis treatments

Multiple studies are evaluating novel drug combinations and their impact on patient outcomes.

02 Gastrointestinal Research

Comprehensive studies on inflammatory bowel conditions, with particular focus on Crohn's Disease and Ulcerative Colitis treatments using innovative biological therapies.

  • Novel therapeutic combinations for IBD
  • Primary sclerosing cholangitis treatments
  • Colorectal cancer interventions

Research aims to improve treatment outcomes and quality of life for patients with chronic gastrointestinal conditions.

03 Women's Health Studies

Advanced research in women's health, including studies on hormonal contraception, menopause management, and reproductive health conditions.

  • Brain effects of contraceptives
  • Treatment for menstrual pain
  • Menopausal hormone therapy safety

These trials focus on developing safer and more effective treatments for women's health concerns.

Back to SwedenAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.